市場調查報告書
商品編碼
1471252
微載體市場:按產品、應用和最終用戶分類 - 2024-2030 年全球預測Microcarriers Market by Product (Consumables, Equipment), Application (Biologics Manufacturing, Cell Therapy, Vaccine Manufacturing), End User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年微載體市場規模為21.6億美元,2024年將達23.7億美元,2030年將達42.2億美元,複合年成長率為9.99%。
微載體是由聚葡萄糖、聚苯乙烯、明膠和玻璃等材料製成的小球形珠子,為貼壁依賴性細胞附著和生長提供表面。這些顆粒的尺寸範圍為 100 至 300 μm,可用於反應器和其他細胞培養系統,以提高細胞生產過程的擴充性和效率。微載體的主要目的是促進需要基材進行黏附和增殖的貼壁依賴性細胞的大規模增殖。在生物技術中,微載體對於生產治療性蛋白質、疫苗和基於細胞的治療方法(例如幹細胞和免疫細胞)至關重要。微載體具有較高的表面積與體積比,與平面上傳統的2D (2D) 單層培養相比,可以更有效地利用反應器內的培養基和空間。考慮到幹細胞在再生醫學、組織工程和藥物發現的潛力,對更有效的培養系統的需求日益成長。微載體已成為大規模擴增多功能細胞(PSC)的關鍵要素。 PSC 可以分化成多種細胞類型,提供商業性製造所需的可擴展性和穩健性。此外,免疫療法也取得了顯著進展,嵌合嵌合體受體(CAR)T細胞療法等過繼性細胞轉移療法在癌症治療中顯示出顯著的臨床療效。與這些治療相關的挑戰之一是無法為治療應用提供足夠數量的高品質免疫細胞。然而,隨著新的細胞治療方法不斷出現並走向實用化,微載體技術預計仍將是其成功製造的關鍵要素。
主要市場統計 | |
---|---|
基準年[2023] | 21.6億美元 |
預測年份 [2024] | 23.7億美元 |
預測年份 [2030] | 42.2億美元 |
複合年成長率(%) | 9.99% |
基於微載體的設備創新,提高產品可擴展性和生產製程彈性
在微載體技術中,產品分為消耗品和設備。消耗品直接影響細胞生長和維持,包括微載體、培養基、血清、緩衝液/試劑和拋棄式。另一方面,反應器、細胞成像系統/細胞計數器和離心/過濾裝置等設備對於使用微載體的細胞培養系統的有效運作至關重要。研究人員優先考慮高品質的產品,以確保最佳的細胞生長,同時保持無菌。因此,由於污染風險降低且易於擴展,因此優選無血清培養基、化學成分確定的培養基和一次性反應器。
應用微載體在生物醫學應用的廣泛使用,在組織工程和再生醫學的潛在應用
微載體在生物技術、製藥和再生醫學領域的各種應用中發揮著重要作用。它支持大規模細胞培養、提高疫苗生產效率、實現組織工程方法、促進藥物發現活動以及促進基因治療進步的能力使其在現代生命科學研究和開發中發揮重要作用。在生技藥品製造中,微載體促進貼壁細胞的生長,以製造蛋白質和單株抗體等大分子。微載體支持間質幹細胞(MSC) 和嵌合體抗原受體 T 細胞 (CAR-T) 等治療細胞的規模化生產。微載體顯示出組織工程應用的潛力,因為它們能夠支援類似於天然組織架構的3D 環境。 CAR-T細胞透過允許多種細胞類型的空間組織、促進細胞間通訊並支持細胞外基質沉積,為創建功能性組織提供了絕佳的平台。在再生醫學中,基於微載體的系統可用於擴增幹細胞,以產生足夠的細胞用於針對器官修復或替代的治療。在疫苗生產中,微載體能夠使貼壁細胞生長,產生疫苗配方所需的病毒載體和抗原。整體而言,每種應用都需要具有獨特特性的客製化微載體解決方案,以滿足不同的要求。透過專注於在生技藥品製造中生產高品質蛋白質、推進細胞治療中的再生醫學以及應對疫苗製造中的全球公共衛生挑戰,製造商正在提高這些關鍵救生技術的效率,並不斷創新以改進我們的技術。
最終用戶:醫療機構中微載體的使用重點在於其性能的準確性和擴充性。
參與細胞培養和疫苗製造的委外研發機構(CRO) 和研究機構依靠創新、高效的生物製程技術來進行研究、藥物發現和臨床前測試。 CRO 特別受益於支持細胞培養規模擴大的微載體,這對於高通量篩檢和最佳化治療藥物生產至關重要。在研究實驗室中,微載體用於促進貼壁依賴性細胞增殖,這對於研究細胞行為和開發組織工程應用非常重要。同時,製藥和生物技術公司主要利用微載體技術生產疫苗、治療性蛋白質和再生藥物。製藥業對效率和成本效益的追求需要能夠適應大型生產設施並與自動化系統無縫整合的微載體。
區域洞察
美洲、歐洲、亞太地區和中東非洲不斷成長的市場證明了對微載體的高需求。以美國為代表的美洲地區擁有先進的生物技術基礎設施和政府對研究活動的大力支持。歐盟 (EU) 優先資助與醫療保健相關的研究舉措,從而導致基於微載體的細胞治療技術的需求增加和進步。在中東和非洲,醫療基礎設施的改善和政府投資激發了人們對微載體應用的興趣。亞太地區,特別是中國和日本的成長是由政府主導推動的,包括新材料的專利申請和高品質微載體的表面改性。此外,印度快速擴張的製藥業刺激了對利用微載體的更先進細胞培養技術的需求。隨著全球對細胞療法的需求持續成長,對微載體等高效生產系統的需求也日益成長。這些為高效微載體系統的開發和部署以及不同地區相關人員之間的新合作創造了重要的創新機會。
FPNV定位矩陣
FPNV定位矩陣對於評估微載體市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對微載體市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭力評估及資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1. 微載體市場的市場規模與預測為何?
2.在微載體市場的預測期間內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.微載體市場的技術趨勢與法規結構是什麼?
4.微載體市場主要廠商的市場佔有率為何?
5. 進入微載體市場的合適型態和策略手段是什麼?
[183 Pages Report] The Microcarriers Market size was estimated at USD 2.16 billion in 2023 and expected to reach USD 2.37 billion in 2024, at a CAGR 9.99% to reach USD 4.22 billion by 2030.
Microcarriers are small spherical beads made from materials such as dextran, polystyrene, gelatin, or glass that provide a surface for anchorage-dependent cells to adhere and grow. These particles range in size from 100 to 300 micrometers and can be used in bioreactors or other cell culture systems to enhance the scalability and efficiency of cell production processes. The primary purpose of microcarriers is to facilitate the large-scale expansion of anchorage-dependent cells that require a substrate for attachment and growth. In biotechnology, microcarriers are essential for producing therapeutic proteins, vaccines, and cell-based therapies, such as stem cells or immune cells. Microcarriers provide a high surface-to-volume ratio, allowing more efficient use of culture medium and space in bioreactors than traditional two-dimensional (2D) monolayer cultures on flat surfaces. There has been an increasing need for more efficient systems for the cultivation of stem cells, given their potential in regenerative medicine, tissue engineering, and drug discovery. Microcarriers have emerged as a key component in the large-scale expansion of pluripotent stem cells (PSCs), which can differentiate into numerous cell types and provide the scalability and robustness required for commercial manufacturing. Moreover, immunotherapy has grown tremendously, with adoptive cell transfer treatments such as chimeric antigen receptor (CAR) T-cell therapy demonstrating significant clinical results in cancer treatment. One of the challenges associated with these therapies is the inability to provide sufficient quantities of high-quality immune cells for therapeutic application. However, as new cell-based therapies continue to emerge and advance toward commercialization, microcarrier technology is expected to remain a critical component driving their manufacturing success.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.16 billion |
Estimated Year [2024] | USD 2.37 billion |
Forecast Year [2030] | USD 4.22 billion |
CAGR (%) | 9.99% |
Product: Innovations in the microcarrier-based equipment for increasing scalability and production process flexibility
In microcarrier technology, products are categorized into consumables and equipment. Consumables, which directly impact cell growth and maintenance, consist of microcarriers, media, sera, buffers/reagents, and disposables. On the other hand, equipment is crucial for efficient microcarrier-based cell culture systems operation which includes bioreactors, cell imaging systems/cell counters, and centrifugation/filtration devices. Researchers prioritize high-quality products ensuring optimal cell growth while maintaining sterility. Consequently, serum-free or chemically-defined media and disposable bioreactors gain preference due to reduced contamination risks and scalability ease.
Application: Extensive usage of microcarriers in biomedical applications, with potential applications in tissue engineering and regenerative medicine
Microcarriers play a crucial role in various applications across biotechnology, pharmaceuticals, and regenerative medicine sectors. Their ability to support large-scale cell cultivation, improve vaccine production efficiency, enable tissue engineering approaches, facilitate drug discovery efforts, and contribute to gene therapy advancements highlights their significance in modern life science research and development. In biologics manufacturing, microcarriers facilitate the growth of adherent cells for producing large molecules, such as proteins and monoclonal antibodies. Microcarriers support scalable production of therapeutic cells, including mesenchymal stem cells (MSCs) and chimeric antigen receptor T-cells (CAR-T). Microcarriers have shown potential in tissue engineering applications due to their ability to support a 3D environment resembling native tissues' architecture. They offer an excellent platform for generating functional tissues by enabling the spatial organization of multiple cell types, promoting cell-cell communication, and supporting extracellular matrix deposition. In regenerative medicine, microcarrier-based systems can be employed in stem cell expansion to produce sufficient cells required for therapies targeting organ repair or replacement. For vaccine manufacturing, microcarriers enable the expansion of adherent cells responsible for producing viral vectors or antigens necessary for vaccine formulation. Overall, each application demands tailored microcarrier solutions with unique properties to address diverse requirements. Manufacturers continuously innovate to improve the efficiency of these crucial life-saving technologies by catering to biologics manufacturing's focus on high-quality protein production; cell therapy's emphasis on regenerative medicine advancements; and vaccine manufacturing's response to global public health challenges.
End User: Utilization of microcarriers in healthcare institutions in preference to their performance accuracy and scalability
Contract research organizations (CROs) and research institutes involved in cell culture and vaccine production rely on innovative and efficient bioprocessing technologies to conduct research, drug discovery, and preclinical trials. CROs particularly benefit from microcarriers as they support the scale-up of cell cultures, which is essential for high-throughput screening and optimizing therapeutic production. Research institutes use microcarriers to facilitate the growth of anchorage-dependent cells, which is important for studying cell behavior and developing tissue engineering applications. On the other hand, pharmaceutical and biotechnology companies leverage microcarrier technology primarily to produce vaccines, therapeutic proteins, and regenerative medicines. The pharmaceutical industry, aiming for efficiency and cost-effectiveness, demands microcarriers compatible with large-scale production facilities and can integrate seamlessly with automated systems.
Regional Insights
Microcarriers are in high demand, as evidenced by their increasing market growth in the Americas, Europe, the Asia-Pacific, and the Middle East and Africa regions. The Americas region, led by the United States, boasts advanced biotechnology infrastructure and strong government support for research activities. The European Union prioritizes funding for healthcare-related research initiatives, resulting in increased demand and advancements in cell therapy technologies that utilize microcarriers. In the Middle East and Africa, improved healthcare infrastructure and government investments have sparked interest in the application of microcarriers. The Asia-Pacific region, particularly China and Japan, is experiencing growth driven by government initiatives, including patent filings for novel materials and surface modifications for high-quality microcarriers. Additionally, India's rapidly expanding pharmaceutical sector is stimulating the need for more advanced cell culture technologies that utilize microcarriers. As the global demand for cell-based therapies continues to rise, there is an increasing need for efficient production systems such as microcarriers. These create significant opportunities for innovation in the development and implementation of efficient microcarrier-based systems and new collaboration among stakeholders in various regions.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Microcarriers Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Microcarriers Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Microcarriers Market, highlighting leading vendors and their innovative profiles. These include Aber Instruments Ltd., Bangs Laboratories, Inc., Bio-Rad Laboratories, Inc., Carroucell, ChemoMetec A/S, Cole-Parmer Instrument Company, Corning Inc., Cytiva, denovoMATRIX GmbH, Entegris, Inc., Eppendorf AG, Esco Vaccixcell, FUJIFILM Holdings Corporation, Getinge AB, Irvine Scientific, Kuraray Co., Ltd., Lonza Group AG, Matrix F.T., Merck KGaA, Modern Meadow Inc., nanoComposix, Inc., Pall Corporation, Polysciences Inc., PromoCell GmbH, Repligen Corporation, RoosterBio, Inc., Sartorius AG, Sunresin New Materials Co.Ltd., Teijin Limited, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Microcarriers Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Microcarriers Market?
3. What are the technology trends and regulatory frameworks in the Microcarriers Market?
4. What is the market share of the leading vendors in the Microcarriers Market?
5. Which modes and strategic moves are suitable for entering the Microcarriers Market?